Exelixis Stock

Exelixis Gross Margin

The Gross Margin of Exelixis (EXEL) as of Aug 19, 2026 is 96.39 %. In the previous year, Gross Margin was 96.49 % — a change of -0.10% (lower).

Gross Margin

96.39 %

YoY

-0.10%

Last updated:

Gross Margin of Exelixis is 2026 96.39 % . Gross Margin of Exelixis was 2025 96.49 % . It decreases by -0.10% lower compared to the previous year.

For Exelixis, the gross margin of 96.4% is broadly stable versus 96.3% a few years ago.

Access this data via the Eulerpool API

Exelixis Stock analysis

What does Exelixis do? Exelixis Inc. is a biopharmaceutical company that specializes in researching and developing drugs for various types of cancer. The company was founded in 1994 and is headquartered in Alameda, California. It has brought several drugs to the market over the years that have had a positive impact on thousands of patients. The company's founders, Corey Goodman, George Scangos, and John Walker, previously worked at Genentech and decided to start their own company to focus on cancer research and drug development. Exelixis Inc. has had numerous successes since its inception, including the development of Cabozantinib, a drug used to treat various types of cancer such as thyroid cancer, kidney cancer, and advanced prostate cancer. The company also has several drug candidates in clinical testing. Its business model revolves around researching and developing drugs that target proteins and signaling pathways overactivated in cancer cells. Exelixis Inc. often collaborates with other companies in the pharmaceutical industry to share development costs and risks. The company is divided into different divisions to treat various cancer types, including kidney, liver, thyroid, and lung cancer. One of its significant milestones was the approval of Cabozantinib by the FDA in 2012 for the treatment of advanced kidney and thyroid cancer. The drug has since been approved in other countries and has been successful in treating different types of cancer. Exelixis Inc. is dedicated to developing better and more effective cancer drugs to help patients. It works closely with doctors, researchers, and other pharmaceutical companies to constantly explore new approaches to combat cancer cells. In summary, Exelixis Inc. is a leading player in the research and development of drugs for various types of cancer. It has a track record of approved drugs and a pipeline of innovative drug candidates. The company's goal is to help cancer patients and contribute to improving people's health. Exelixis is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Exelixis stock

Gross Margin of Exelixis is 96.39 % in 2026.

Gross Margin of Exelixis changed from 96.49 % to 96.39 %, representing a -0.10% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Gross Margin Exelixis since 2006 – with annual values, charts, and detailed analysis.

Gross Margin measures the percentage of revenue remaining after COGS. Higher gross margins indicate more efficient production and stronger pricing power.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Gross Margin's Exelixis with sector peers and the industry average to assess whether it is attractive.

To evaluate Gross Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Gross Margin.

Access this data via the Eulerpool API

Margins — Exelixis

All Key Metrics — Exelixis